Effectiveness and Persistence in SB4‐ and Reference Etanercept–Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway
Main finding · Change from baseline in DAS28, unmatched analysisResult — go to the resultMean difference −0.02 95% CI −0.32 to 0.27Authors' conclusion
Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with etanercept or SB4 between 2010 and 2018 at 5 centers in Norway with ≥1 year of follow-upmatched analyses n = 172
- Participants
- 1,455 patients
- Exposure
- SB4 vs reference etanercept
- SB4n = 299
- Etanerceptn = 575reference
- Outcome
- Change from baseline in DAS28
- Follow-up
- Week 52
Methodological detailscomparative effectiveness, propensity-score matched, multicentre (5 centers), EULAR Points to Consider for Comparative Effectiveness Research, equivalence margin ±0.6
- Comparative effectiveness
- Propensity-score matched
- Multicentre (5 centers)
- EULAR Points to Consider for Comparative Effectiveness Research
- Equivalence margin ±0.6
Main finding
As reported in the abstract
Change from baseline in DAS28, unmatched analysis
Mean difference
−0.02
95% CI −0.32 to 0.27
Etanerceptvs SB4
mean difference −0.02 (95% CI −0.32 to 0.27)
Observational data: associations, not effects.
Further findings
| Outcome | Difference (95% CI) | |
|---|---|---|
| Change from baseline in DAS28, PS-matched analysis · week 52n = 49 each; within predefined equivalence margin · propensity-score matched | 0.03 (−0.46 to 0.52) | |
| −0.500.51Difference (linear scale) |
| Outcome | Etanercept | SB4 |
|---|---|---|
| Drug persistence, unmatched analysis · week 52Unmatched analysis | 0.62 (95% CI 0.57–0.65) | 0.66 (95% CI 0.60–0.71) |
| Drug persistence, PS-matched analysis · week 52Propensity-score matched | 0.52 (95% CI 0.44–0.59) | 0.68 (95% CI 0.61–0.75) |
Drug persistence, unmatched analysis · week 52
- Persistence similar between cohorts
Original publication
Effectiveness and Persistence in SB4‐ and Reference Etanercept–Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway. Arthritis Care Res (Hoboken). Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →